| 宋 朋,高树庚.ⅠB期NSCLC术后辅助化疗争议及病理预后因素[J].中国肿瘤,2017,26(4):286-290. |
| ⅠB期NSCLC术后辅助化疗争议及病理预后因素 |
| Adjuvant Chemotherapy and Pathological Prognostic Factors in Patients with Non-small Cell Lung Cancer Stage ⅠB |
| 投稿时间：2016-10-11 |
| DOI：10.11735/j.issn.1004-0242.2017.04.A009 |
|
 |
| 中文关键词: 非小细胞肺癌 辅助化疗 预后因素 |
| 英文关键词:non-small cell lung cancer adjuvant chemotherapy prognostic factor |
| 基金项目: |
|
| 摘要点击次数: 1778 |
| 全文下载次数: 605 |
| 中文摘要: |
| 摘 要：ⅠB期非小细胞肺癌(NSCLC)为早期肺癌，目前最有效的治疗手段为手术治疗。然而，肿瘤的复发仍严重影响ⅠB期非小细胞肺癌患者的术后长期生存。ⅠB期NSCLC患者能否从辅助化疗中获益仍存在争议，本文就ⅠB期NSCLC患者术后辅助化疗存在的争议及影响预后的病理学特征做一综述。 |
| 英文摘要: |
| Abstract：Non-small cell lung cancer stage ⅠB is early-stage lung cancer and surgery is regarded as the best possible treatment for patients with NSCLC stage ⅠB. However，postoperative long-term survival remains unsatisfactory due to high frequency of recurrence. The benefit of adjuvant chemotherapy in patients with NSCLC stage ⅠB is controversial. This review focuses on the controversy regarding the adjuvant chemotherapy and pathological prognostic factors of NSCLC stage ⅠB. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |